Amgen has earned top marks in Zacks Style Scores for value investors, driven by a forward price-to-earnings ratio of 16x, below the industry median of 19x. Its dividend yield of 3.1% ranks in the top decile of large-cap biopharma firms. Over the past 12 months, Amgen’s free cash flow improved by 18%, reaching $8.2 billion, bolstering its capacity to sustain shareholder distributions and fund pipeline development. The company’s price/book ratio of 4.5 compares favorably to the sector average of 6.2, underscoring its market appeal for investors focused on valuation metrics.

Analysts forecast Amgen’s Q4 revenue to climb 6% year-over-year, with sales of its flagship oncology and inflammation drugs expected to account for roughly 70% of total revenues. Consensus estimates project non-GAAP earnings per share of $5.10, up from $4.85 in the prior year period, reflecting margin expansion from operational efficiencies. Wall Street is watching inventory trends, with channel stocking anticipated to add up to $200 million in product shipments. R&D spending is set to remain elevated at approximately $3.5 billion for the full year, driven by late-stage clinical trials for pipeline candidates.

Amgen’s experimental GLP-1 therapy, MariTide, delivered average patient weight loss of 15% in Phase II trials—comparable to weekly injectable peers—while offering a quarterly dosing regimen. If approved, MariTide could capture 5% to 7% of the $75 billion global GLP-1 market by 2028, according to internal forecasts. The program has attracted an estimated $1.2 billion in milestone-based co-development funding from a major pharmaceutical partner, partially de-risking the project and potentially accelerating commercial launch preparations.